Latest news

Latest news and references to SMP2 and the National Lung Matrix Trial. 

World Conference on Lung Cancer 2019

Description
World Conference on Lung Cancer 2019
Date:
17/12/2019

16th June 2017, ECMC Announcement - SMP2 and NLMT programme updates

Description
ECMC Announcement - SMP2 and NLMT programme updates
Date:
20/11/2017

CRUK Science Blog – Behind the scenes with the unsung heroes of cancer clinical trials – Part 4 (Interview with Jane Hair - Biobanker)

CRUK Science Blog – Behind the scenes with the unsung heroes of cancer clinical trials – Part 4 (Interview with Jane Hair - Biobanker)
Description
In this post, Jane Hair, a biobanker who works at the biorepository unit in Glasgow, and is involved in the National Lung Matrix Trial, shares what her job involves.
Date:
23/05/2017

ECMC Announcement – Over 1,800 lung cancer patients screened through stratified medicine initiative

ECMC Announcement – Over 1,800 lung cancer patients screened through stratified medicine initiative
Description
Over 1,800 patients have been screened through the Stratified Medicine Programme Phase 2 (SMP2), with the 100th patient being recruited to the National Lung Matrix Trial (NLMT) in November 2016.
Date:
21/12/2016

ECMC Announcement – Stratified Medicine Programme 2 update

ECMC Announcement – Stratified Medicine Programme 2 update
Description
The National Lung Matrix Trial (NLMT) is the first UK trial to combine the development of a technology platform that screens for multiple genetic aberrations in tumours (provided by CRUK's SMP2) with testing of multiple novel genetic-marker-directed drugs.
Date:
27/10/2016

Annals of Oncology Publication

Description
The National Lung Matrix Trial: translation the biology of stratification in advanced non-small cell lung cancer
Date:
25/09/2016

ECMC Announcement – National Lung Matrix Trial update

ECMC Announcement – National Lung Matrix Trial update
Description
The National Lung Matrix Trial (NLMT) is a flagship trial in the UK, being the first to combine the development of a technology platform that screens for multiple genetic aberrations in tumours (provided by CRUK's Stratified Medicine Programme 2) with testing of multiple novel genetic-marker-directed drugs.
Date:
11/08/2016

ECMC Announcement – Stratified Medicine Programme Phase 2 update

ECMC Announcement – Stratified Medicine Programme Phase 2 update
Description
The CRUK Stratified Medicine Programme Phase 2 (SMP2) is the national pre-screening study to the National Lung MATRIX Trial (NLMT).
Date:
17/06/2016

ECMC Announcement – National Lung Matrix Trial update

ECMC Announcement – National Lung Matrix Trial update
Description
The National Lung Matrix Trial (NLMT) is a flagship precision medicine trial, funded by CRUK, and supported by the Stratified Medicine Programme Phase 2 (SMP2) screening platform. It is to our knowledge currently the largest precision medicine trial globally.
Date:
05/04/2016
Displaying 1 to 9 of 9